Core Insights - Myriad Genetics reported revenue of $213.1 million for the quarter ended June 2025, marking a year-over-year increase of 0.8% and exceeding the Zacks Consensus Estimate of $201.9 million by 5.55% [1] - The company achieved an EPS of $0.05, which is consistent with the EPS from the same period last year, and delivered a significant EPS surprise of 600% compared to the consensus estimate of -$0.01 [1] Revenue Breakdown by Core Product - Prenatal revenue reached $47.6 million, slightly below the average estimate of $49.93 million, reflecting a year-over-year increase of 10.7% [4] - Hereditary Cancer revenue was $96.3 million, surpassing the average estimate of $88.37 million, with a year-over-year growth of 5.3% [4] - Pharmacogenomics revenue totaled $37.8 million, exceeding the average estimate of $32.08 million, but showing a year-over-year decline of 12.1% [4] - Tumor Profiling revenue was reported at $31.4 million, closely aligning with the average estimate of $31.31 million, and indicating a year-over-year decrease of 3.7% [4] Stock Performance - Myriad's shares have declined by 24.8% over the past month, contrasting with a 1% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Company Performance - Myriad Genetics reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of a loss of $0.01 per share, representing an earnings surprise of +600.00% [1] - The company posted revenues of $213.1 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.55% and showing a slight increase from $211.5 million year-over-year [2] - Over the last four quarters, Myriad has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Outlook - Myriad shares have declined approximately 71% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $205.1 million, while for the current fiscal year, the estimate is -$0.01 on revenues of $811.68 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Myriad belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Myriad's stock performance [5]

Financial Data and Key Metrics Changes - The company reported revenue of $213 million for Q2 2025, representing a 5% year-over-year increase, excluding the impact of UnitedHealthcare's decision on GeneSight and the divested European ENDOPREDICT business [7][34] - Adjusted gross margins improved to 71.5%, an increase of 140 basis points compared to the previous year [12][38] - Adjusted EBITDA for the quarter was $14.5 million, reflecting a 24% growth year-over-year [12][45] Business Line Data and Key Metrics Changes - Hereditary cancer revenue grew by 5% for the quarter, with a 10% volume growth in the oncology channel [23] - GeneSight volume increased by 5% year-over-year, recovering from low single digits [10][31] - Prenatal products, PREQUEL and FORESIGHT, saw a 7% decline in volume year-over-year due to challenges with an order management system, which has since been resolved [11][29] Market Data and Key Metrics Changes - The oncology market showed strong growth, with hereditary cancer testing volume increasing by 14% year-over-year [9][25] - The prenatal health market is expected to grow at or above market rates, driven by new product launches and expanded payer coverage [19][30] - Mental health testing through GeneSight generated revenues of $38 million, with a 5% volume growth year-over-year [31] Company Strategy and Development Direction - The company is focusing on the cancer care continuum (CCC) as a strategic priority to drive accelerated growth and profitability [14][15] - Three strategic pillars include enhancing hereditary cancer testing, growing prenatal and mental health revenues, and maintaining financial discipline [18][20] - The company plans to increase investments in R&D and enhance commercial capabilities to support the CCC strategy [17][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's potential and the progress made in addressing previous challenges [6][8] - The company raised its guidance for 2025 based on positive Q2 results and ongoing improvements in execution [13][45] - Management emphasized the importance of strategic partnerships and operational excellence to drive future growth [17][22] Other Important Information - The company secured a $200 million term loan from OrbiMed, providing liquidity and flexibility for growth initiatives [13][43] - A significant non-cash impairment charge of $317 million was recognized due to a decline in market capitalization, but this does not reflect a change in business outlook [39][40] Q&A Session Summary Question: Request for more specific KPIs related to the strategic review - Management acknowledged the need for more quantifiable KPIs and plans to share these in the upcoming months [52][56] Question: Clarification on portfolio divestitures - Management indicated satisfaction with the current portfolio and stated that periodic reviews will be conducted to assess strategic alignment [53][56] Question: Impact of UnitedHealthcare's coverage on GeneSight - Management confirmed ongoing discussions with UnitedHealthcare and plans to submit new clinical data for review in the fall [60][64] Question: Clarification on the timing of the MRD test launch - Management confirmed an early access launch for the MRD test in the first half of 2026, with ongoing clinical studies [66][68] Question: Guidance for the back half of the year - Management indicated that the guidance raise is based on improved execution and recovery from previous challenges, particularly in hereditary cancer testing [88][90]

Q2 2025 Financial Performance - Q2 2025 revenue reached $213.1 million, driven by strong average revenue per test trends[6] - Adjusted gross margins in Q2 2025 were 71.5%, a year-over-year increase of 140 basis points[6] - Adjusted operating expenses in Q2 2025 grew by 2% year-over-year, reflecting a focus on managing discretionary spending[6] - Adjusted EBITDA for Q2 2025 was $14.5 million, representing a 24% year-over-year growth[6] - Adjusted EPS for Q2 2025 was $0.05[6] Revenue Growth and Guidance - The company is raising its 2025 revenue guidance range, with underlying total revenue growth of 5% year-over-year[9] - Oncology hereditary cancer test revenue grew by 9% year-over-year, driven by a 10% volume growth year-over-year[9] - Total potential liquidity is estimated at $205.9 million, including $74.4 million in cash and cash equivalents at the end of Q2 2025 and access to a new credit facility[44] Strategic Focus - The company is focusing on high-growth Cancer Care Continuum (CCC) segments to accelerate growth[9, 12, 14] - The company aims to grow revenue at or above market in Prenatal & Mental Health[9, 16] - The company is focused on sustained profitable growth[9, 12, 18]

Exhibit 99.1 Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights SALT LAKE CITY, August 5, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2025 and updated its financial guidance on business performance for the full-year 2025. Attributable to UNH discontinuation of coverage (commercial and ...

Core Insights - Myriad Genetics reported solid second-quarter results, driven by strong hereditary cancer testing in oncology and favorable pricing trends, while also updating its financial guidance for the full year 2025 [2][3] Financial Performance - Second quarter 2025 revenue was $213.1 million, a 1% increase year-over-year, with a 5% increase when excluding headwinds of $9.5 million [5] - Hereditary cancer testing revenue and volume in oncology grew by 9% and 10% year-over-year, respectively, with MyRisk with RiskScore testing volume in oncology increasing by 14% [5][17] - Gross margin for the second quarter 2025 was 71.2%, up over 160 basis points year-over-year, benefiting from product mix and improved laboratory efficiencies [5] - The company reported a GAAP net loss of $330.5 million, or $(3.57) per share, primarily due to non-cash impairment charges of $316.7 million [5][11] - Adjusted EPS for the second quarter 2025 was $0.05 [5] Strategic Update - Myriad Genetics is focusing on the Cancer Care Continuum (CCC) to accelerate growth, with plans to expand its test portfolio into therapy selection and immuno-oncology therapy response monitoring [6] - The company aims to grow revenue in Prenatal Health and Mental Health while maintaining disciplined investment in these areas [7] - Myriad Genetics expects to achieve high single-digit to low double-digit revenue growth and increased profitability over the next five years [7] Business Unit Performance - The Oncology business generated revenue of $85.5 million in the second quarter of 2025 [13] - The Women's Health business reported revenue of $89.8 million in the same period [14] - GeneSight test revenue was $37.8 million, with a 5% year-over-year growth in test volume, despite the impact of UnitedHealthcare's decision to discontinue coverage [15] Financial Guidance - The company raised its 2025 revenue guidance to a range of $818 - $828 million, up from $807 - $823 million, reflecting improved business outlook [19] - Adjusted operating expenses for 2025 are projected to be between $562 - $568 million [19] - Adjusted EBITDA guidance was increased to a range of $27 - $33 million [19]

Core Insights - Myriad Genetics has secured a five-year senior secured term loan credit facility of up to $200 million from OrbiMed, which includes $125 million of funded capital and an option to borrow an additional $75 million until June 30, 2027 [1][2] - The facility matures on July 31, 2030, and has an interest rate based on the one-month secured overnight financing rate (SOFR) plus 6.50%, with a SOFR floor of 2.50% [1] - The new credit facility replaces Myriad's previous asset-based lending (ABL) facility and is secured by substantially all the assets of Myriad Genetics and its subsidiaries [2] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being through molecular tests that assess disease risk and guide treatment decisions [3] - The company aims to improve patient care and reduce healthcare costs through its diagnostic tests [3] Partner Overview - OrbiMed is a prominent healthcare investment firm with over $17 billion in assets under management, investing globally across the healthcare industry [4] - The firm provides tailored financing solutions and extensive resources to support the growth of healthcare companies [4]

Core Points - Myriad Genetics, Inc. will hold its second quarter 2025 earnings conference call on August 5, 2025, at 4:30 PM ET [1] - The company's quarterly earnings will be released the same day after market close [1] - Management will provide a financial overview and business update during the call [1] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine [3] - The company develops molecular tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3] Investor Information - A live webcast of the conference call will be available on Myriad's Investor Relations website [2] - Participants can register for the call to receive a dial-in number and unique PIN [2] - An archived version of the webcast will be accessible after the call [2]

Company Overview - Myriad Genetics, Inc. is a leader in molecular diagnostic testing and precision medicine, dedicated to advancing health and well-being for all [7] - The company develops and offers molecular tests that help assess disease risk and guide treatment decisions, significantly improving patient care and lowering healthcare costs [7] Employee Experience - Myriad Genetics has received the Great Place to Work Certification for the third consecutive year, with 84% of employees affirming it as a great workplace, which is 30 percentage points higher than the average U.S. company [1][3] - The focus on inclusivity and caring is highlighted by employee resource groups that foster connection and support among employees [2] - The certification reflects the passion and dedication of Myriad's teammates, emphasizing a workplace where every employee feels connected, supported, and empowered [3] Recognition and Certification - The Great Place to Work Certification is a prestigious recognition based solely on employee feedback regarding workplace experience and trust [4] - Over 10,000 companies across 60 countries apply for this certification annually, making it a global benchmark for outstanding employee experience [4][5] - Myriad Genetics' achievement of this certification indicates its status as one of the top companies to work for, providing a positive workplace environment [3]

Core Insights - Holzer & Holzer, LLC is investigating Myriad Genetics for potential compliance issues with federal securities laws following a significant decline in pharmacogenomics revenue [1] - Myriad Genetics reported a 20% year-over-year decline in pharmacogenomics revenue attributed to UnitedHealthcare reducing coverage of GeneSight [1] - The company's stock price dropped after the announcement of its first quarter 2025 financial results and lowered financial guidance [1]